Cstone Pharmaceuticals · HKEX:2616
Cstone Pharmaceuticals — H1 2021 Earnings Presentation
31 slides from Cstone Pharmaceuticals's earnings presentation, Aug 27, 2021
Slide 1: 2021 Interim Results Presentation
2616.HK 2021 Interim Results Presentation 10am-11am Aug 27th, 2021 (Hong Kong Time) 1
Slide 2: Agenda
Agenda Section Presenter Dr. Frank Jiang Chairman, Chief Executive Officer Management Presentation Mr. Daniel Weng Head of Finance Dr. Frank Jiang Chairman, Chief Executive Officer Dr. Shirley Zhao Greater China GM Dr. Jason Yang Chief Medical Officer Q&A Dr. Archie Tse Chief Scientific Officer Mr.
Slide 3: Presentation Disclaimer
Presentation Disclaimer By attending the meeting where this presentation is made, or by reading the presentation materials, you agree to be bound by the following: The information in this presentation has been prepared by representatives of CStone Pharmaceuticals (the "Company" and, together with it
Slide 4: Introduction & Overview
Introduction & Overview 4
Slide 5: 2021YTD Business Highlights
Introduction & Overview 2021YTD Business Highlights Successfully launched two FIC products, achieving significant sales in a short period of time. AYVAKIT® (avapritinib) launched in mainland China and Taiwan, China in Commercial May and June, respectively. GAVRETO® (pralsetinib) launched in mainland
Slide 6: Full-fledged Biopharma
Introduction & Overview 2616.HK Full-fledged Biopharma 5 Years Since Company Inception Industry leading management Solid financial position and team with proven track record ability to support growth and complementary expertise initiatives Well-balanced oncology portfolio with 15 immuno- Full-fledge
Slide 7: Industry leading management team
Introduction & Overview Industry leading management team Leadership with proven track record and complementary expertise Frank Jiang, MD, PhD Chairman, Chief Executive Officer Shirley Zhao, MD, MBA Jason Yang, MD, PhD Greater China GM Chief Medical Officer Archie Tse, MD, PhD Jingrong Li, PhD Chief
Slide 8: Well-balanced oncology portfolio of 15 innovative assets
Introduction & Overview Well-balanced oncology portfolio of 15 innovative assets Focused on immuno-oncology and precision medicine Approval Drug candidate Rights Indication Pre-clinical FIH POC Pivotal NDA Marketed Partner CN5 TW HK US 2L NSCLC Pralsetinib 1L NSCLC (RET) 1L MTC / TC Multiple tumors
Slide 9: Interim Business Review
Interim Business Review 9
Slide 10: Established strong commercial foundation with seasoned industry leaders
Commercial 2 3 4 5 Interim Business Review Established strong commercial foundation with seasoned industry leaders Supporting CStone's oncology leadership with successful launches • 25+ years of experience in the industry (former Greater China GM of BMS, Allergan, Genzyme) • Built several organizati
Slide 11: Launches set industry benchmark for speed of delivery
Commercial 2 3 4 5 Interim Business Review Launches set industry benchmark for speed of delivery Go-to market strategy enabled rapid and broad day one sales MNC CStone Quality Speed GAVRETO® AYVAKIT® Achieved rapid NMPA approval, Time to reach distribution partners 6.5 months within a shorter timefr
Slide 12: Expanding accessibility of assets on the market
Commercial 2 3 4 5 Interim Business Review Expanding accessibility of assets on the market Commercial team taking additional steps to bolster sales growth Reimbursement Coverage Scientific Influence ▪ 20 of the major government and commercial ▪ >7 national treatment & diagnosis guidelines insurance
Slide 13: Bolstering commercial potential of pipeline developments
Commercial 2 3 4 5 Interim Business Review Bolstering commercial potential of pipeline developments Preparing market for indication expansions and upcoming launches Indication expansion of launched assets Launch preparation of more assets GAVRETO® SUGEMALIMAB • NSCLC – 1L RET • NSCLC – Stage III fus
Slide 14: Preparing Sugemalimab for full-scale commercial launch
Commercial 2 3 4 5 Interim Business Review Preparing Sugemalimab for full-scale commercial launch Harnessing Pfizer’s commercial leadership/infrastructure in China US$200mn equity investment with three paths for collaboration Commercialization of Co-development of 1 Sugemalimab 2 Pfizer assets 3 ▪ U
Slide 15: Unrivalled clinical development engine
1 Clinical 3 4 5 Interim Business Review Unrivalled clinical development engine Robust strategy, innovative trial designs and agile execution Jason Yang, MD, PhD, Chief Medical Officer ➢ A physician scientist and senior executive with 25+ years biomedical research and biopharma R&D experience in onc
Slide 16: Poised for rapid growth with numerous clinical successes
1 Clinical 3 4 5 Interim Business Review Poised for rapid growth with numerous clinical successes Industry leading number of NDA submissions, approvals, data readouts Roadmap for new product Indication & geographic expansion of launched products Ivosidenib AML (R/R) Pralsetinib Avapritinib ▪ NDA acc
Slide 17: Expanding addressable patient population for key assets
1 Clinical 3 4 5 Interim Business Review Expanding addressable patient population for key assets Trials for additional indications to unlock full commercial potential ~90,000 1L NSCLC Pralsetinib Avapritinib 2L NSCLC Ivosidenib x225% MTC PTC Basket trial GIST (mPDGFRα） AdvSM ~40,000 ISM x400% 1L NSC
Slide 18: Sugemalimab poised to reshape lung cancer landscape
1 Clinical 3 4 5 Interim Business Review Sugemalimab poised to reshape lung cancer landscape Only PD-(L)1 with efficacy in stage III & IV NSCLC in “all-comers” setting The first PD-(L)1 to cover the entire advanced Positioned to become physicians’ preferred NSCLC through innovative trial design PD-(
Slide 19: Accelerated clinical advancement of sugemalimab
1 Clinical 3 4 5 Interim Business Review Accelerated clinical advancement of sugemalimab Entered the 1st tier of NSCLC from the 12th place with “CStone Speed” From IND to Stage IV NDA approval Cover both Stage III and Stage IV NSCLC 1st PD-(L)1 for the treatment of both stage III 4th PD-(L)1 and IV
Slide 20: Growing BD team expands global partnership network
1 2 BD 4 5 Interim Business Review Growing BD team expands global partnership network Deeper capabilities to support pipeline and commercialization efforts Michael Choi, Chief Business Officer ➢ 23+ years of experience in biopharmaceutical strategy and business development ➢ Executive experience wit
Slide 21: Further deepening our strategic partnership with Pfizer
1 2 BD 4 5 Interim Business Review Further deepening our strategic partnership with Pfizer Agreement to co-develop Lorlatinib strengthens lung cancer offering US$200mn equity investment with three paths for collaboration Commercialization of Co-development of 1 Sugemalimab 2 Pfizer assets 3 ▪ Up to
Slide 22: Preparing sugemalimab for global launch
1 2 BD 4 5 Interim Business Review Preparing sugemalimab for global launch Leveraging EQRx’s business model to penetrate PD-L1 market US$150mn upfront payment, up to US$1.15bn milestone payments and tiered double-digit royalties on net sales ~US$30bn in market value1 (NSCLC, Gastric, Esophageal) Res
Slide 23: Translating innovation into safe and effective therapies
1 2 3 Pipeline 2.0 5 Interim Business Review Translating innovation into safe and effective therapies Accelerating the development of assets from lab to post-POC stage Archie Tse, MD, PhD, Chief Scientific Officer ➢ 20+ years of experience in translational oncology research covering cytotoxics, targ
Slide 24: Harnessing full potential of next-gen candidates
1 2 3 Pipeline 2.0 5 Interim Business Review Harnessing full potential of next-gen candidates Significant progress developing portfolio of FIC/BIC/FW assets ADC PCC Declaration IND Submission CS5001 (ROR1 ADC) 1 of top 3 ADCs globally and the first ADC in China Pre-IND CS5002 (ADC) Potential BIC wit
Slide 25: ROR1 ADC: an asset with transformational potential
1 2 3 Pipeline 2.0 5 Interim Business Review ROR1 ADC: an asset with transformational potential FIC/BIC asset in new modality with highly differentiated features Differentiation In Design Clinical & Business Value Potentially wider ➢ Potential applications for a wide range therapeutic window of tumo
Slide 26: Healthy financial profile supported by solid execution
1 2 3 4 Finance & Capital Markets Interim Business Review Healthy financial profile supported by solid execution Well capitalized for growth initiatives and commercial stage operations • RMB2,447.2 million of cash, cash equivalents and time deposits Cash Balance as of June 30, 2021 • Product revenue
Slide 27: Expanding capital markets access
1 2 3 4 Finance & Capital Markets Interim Business Review Expanding capital markets access Inclusion in key index to support share trading and broaden ownership • Included in Hang Seng Composite • Expect to be included in Hong Kong Index on August 20, 2021, and effective Stock Connect upon the offic
Slide 28: Business Outlook
Business Outlook 28
Slide 29: Vigorous pace of activity for remainder of 2021
Business Outlook Vigorous pace of activity for remainder of 2021 Bringing significant clinical and commercial developments to fruition Pipeline 2.0 Commercial Clinical & Others Preparation for new NDA approvals Data readout / presentation IND filings & approvals product & indication launch • Sugemal
Slide 30: Business outlook for 2022
Introduction & Overview Business outlook for 2022 Unlocking the global potential of our business and portfolio Maximizing commercial potential with market expansion and penetration Commercial Target 5 NDA approvals of products Expedite full slate of clinical development programs Clinical Expect 5+ N
Slide 31: THANK YOU
iin CSTONE HKEX . PHARMACEUTICALS 2616.HK ies ag| Bhay oo O
CStone Pharmaceuticals — H1 2021 Earnings Presentation on 6ix